BLA 050114 · Allerquest
Pre-Pen
Benzylpenicilloyl Polylysine · Injection
NovelLast checked: Nov 20, 2026Latest source record: Jan 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1974
Jul 25, 1974
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
1 Phase 3, 1 recruiting
FAERS reports
35
11 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 12, 2024.
INDICATIONS AND USAGE: PRE-PEN is indicated for the assessment of sensitization to penicillin (benzylpenicillin or penicillin G) in patients suspected to have clinical penicillin hypersensitivity. A negative skin test to PRE-PEN is associated with an incidence of immediate allergic reactions of less than 5% after the administration of therapeutic penicillin, whereas the incidence may be more than 50% in a history-positive patient with a positive skin test to PRE-PEN. These allergic reactions are predominantly dermatologic. Whether a negative skin test to PRE-PEN predicts a lower risk of anaphylaxis is not established. Similarly, when deciding the risk of proposed penicillin treatment, there are not enough data at present to permit relative weighing in individual cases of a history of clinical penicillin hypersensitivity as compared to positive skin tests to PRE-PEN and/or minor penicillin determinants.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 25, 1974 Original approval · Type 1 - New Molecular Entity
1 products under this application
- PRE-PEN · BENZYLPENICILLOYL POLYLYSINE 60UMOLAR · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Benzylpenicilloyl Polylysine" as an intervention, any sponsor and status, largest first.
- Evaluation of Skin Testing Reagents for Penicillin AllergyPivotal-lookingCompleted
AllerQuest LLCIndustry
NCT01818336 · 481 participants · Start Dec 2012 · Primary completion Jun 2013
Drug: Penicillin skin test kit · For: History of IgE Dependent Reaction to a Penicillin Product
Sites: Homewood, Alabama; Tucson, Arizona; Walnut Creek, California · 13 sites in all
- Optimizing the Diagnostic Approach to Cephalosporin Allergy TestingPivotal-lookingRecruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06406114 · 300 participants (planned) · Start May 5, 2025 · Primary completion Jul 1, 2028
Drug: Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge and 3 more · For: Drug Allergy; Cephalosporin Allergy; Drug Hypersensitivity and 4 more
Sites: Scottsdale, Arizona; San Francisco, California; Boston, Massachusetts · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pruritus12
- false negative investigation result9
- urticaria6
- anaphylactic reaction4
- skin test positive4
- erythema3
- feeling hot3
- maternal exposure during pregnancy3
- throat tightness3
- drug hypersensitivity2
- dyspnoea2
- exposure during pregnancy2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 5 |
| 2019 | 6 |
| 2020 | 7 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Alkali-treated penicillin G solution is a better option than penicillin G as an alternative source of minor determinants for penicillin skin test.
Wangrattanasopon P, Ruxrungtham K, Chantaphakul H, et al. · Allergy Asthma Proc 2012 · Comparative Study, Controlled Clinical Trial
- Assessment of a new brand of determinants for skin testing in a large group of patients with suspected beta-lactam allergy.
Matheu V, Pérez E, González R, et al. · J Investig Allergol Clin Immunol 2007 · Clinical Trial
- Preparation of benzylpenicilloyl-polylysine: a preliminary study.
Vemuri P, Harris KE, Suh LA, et al. · Allergy Asthma Proc 2004 · Clinical Trial, Comparative Study
- A pilot study of penicillin skin testing in patients with a history of penicillin allergy admitted to a medical ICU.
Arroliga ME, Wagner W, Bobek MB, et al. · Chest 2000 · Clinical Trial, Comparative Study
Sponsor: Allerquest
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.